

Hanbyoul Cho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5352053/hanbyoul-cho-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74
papers

1,871
citations

22
h-index

41
g-index

78
ext. papers

2,218
ext. citations

4.9
avg, IF

4.47
L-index

#	Paper	IF	Citations
74	Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models.. <i>Cancers</i> , 2022 , 14,	6.6	5
73	NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. <i>Scientific Reports</i> , 2022 , 12,	4.9	1
72	Regulates Chemoresistance in Association With by Inhibiting Apoptosis Pathway in Patients With Cervical Cancer. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 699-713	3.3	1
71	The Combination of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) is an Effective Prognostic Biomarker in Cervical Cancer. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 214-223	3.2	5
70	LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. <i>Autophagy</i> , 2021 , 17, 1978-1997	10.2	6
69	Modulated electro-hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial. <i>Experimental and Therapeutic Medicine</i> , 2021 , 22, 787	2.1	
68	MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. <i>PLoS Pathogens</i> , 2021 , 17, e1009216	7.6	3
67	TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels. <i>Cancers</i> , 2020 , 12,	6.6	6
66	HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. <i>Nature Communications</i> , 2020 , 11, 562	17.4	23
65	Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2020 , 17, 309-319	3.3	4
64	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 211-221	4.9	6
63	Forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) overexpression is associated with poor prognosis in patients with cervical cancer. <i>International Journal of Clinical Oncology</i> , 2019 , 24, 1429-1439	4.2	4
62	ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. <i>Cancers</i> , 2019 , 11,	6.6	8
61	Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer. <i>Cancer Genomics and Proteomics</i> , 2019 , 16, 553-562	3.3	11
60	Association of forkhead box protein O1 and paired box gene 3 overexpression with prognosis in patients with cervical cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14519-e14519	2.2	
59	Prognostic implication of forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) in epithelial ovarian cancer. 2019 , 5, 61-61		
58	Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer. <i>BMC Cancer</i> , 2019 , 19, 1202	4.8	7

57	Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth. <i>International Journal of Hyperthermia</i> , 2019 , 36, 9-20	3.7	10
56	Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF. <i>Cell Death and Differentiation</i> , 2018 , 25, 1050-1062	12.7	46
55	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis. <i>Cancer Research</i> , 2018 , 78, 2638-2653	10.1	22
54	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. <i>Gynecologic Oncology</i> , 2018 , 149, 381-387	4.9	24
53	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. <i>Cancers</i> , 2018 , 10,	6.6	8
52	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4098-4114	15.9	17
51	Histomorphological and Molecular Assessments of the Fixation Times Comparing Formalin and Ethanol-Based Fixatives. <i>Journal of Histochemistry and Cytochemistry</i> , 2018 , 66, 121-135	3.4	20
50	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. <i>Cancer Research and Treatment</i> , 2018 , 50, 956-963	5.2	15
49	Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression. <i>PLoS ONE</i> , 2018 , 13, e0205297	3.7	14
48	Dual loss of USP10 and p14ARF protein expression is associated with poor prognosis in patients with small intestinal adenocarcinoma. <i>Tumor Biology</i> , 2018 , 40, 1010428318808678	2.9	8
47	REP1 inhibits FOXO3-mediated apoptosis to promote cancer cell survival. <i>Cell Death and Disease</i> , 2017 , 8, e2536	9.8	16
46	API5 induces cisplatin resistance through FGFR signaling in human cancer cells. <i>Experimental and Molecular Medicine</i> , 2017 , 49, e374	12.8	13
45	HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. <i>Cancer Research</i> , 2017 , 77, 5039-5053	10.1	57
44	Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e12	4	24
43	Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer. <i>Anticancer Research</i> , 2017 , 37, 4873-4879	2.3	4
42	A melanin-bleaching methodology for molecular and histopathological analysis of formalin-fixed paraffin-embedded tissue. <i>Laboratory Investigation</i> , 2016 , 96, 1116-27	5.9	12
41	The paraffin-embedded RNA metric (PERM) for RNA isolated from formalin-fixed, paraffin-embedded tissue. <i>BioTechniques</i> , 2016 , 60, 239-44	2.5	17
40	Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 49481-49497	3.3	49

39	Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. <i>Yonsei Medical Journal</i> , 2016 , 57, 580-7	3	12
38	Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology. <i>Medicine (United States)</i> , 2016 , 95, e2425	1.8	1
37	PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumorigenesis. <i>Nature Communications</i> , 2015 , 6, 7769	17.4	105
36	Clinical significance of OCT4 and SOX2 protein expression in cervical cancer. <i>BMC Cancer</i> , 2015 , 15, 10154.8	5.8	59
35	Prognostic Significance of AMP-Dependent Kinase Alpha Expression in Cervical Cancer. <i>Pathobiology</i> , 2015 , 82, 203-11	3.6	10
34	Assessment of a panel of tumor markers for the differential diagnosis of benign and malignant effusions by well-based reverse phase protein array. <i>Diagnostic Pathology</i> , 2015 , 10, 53	3	6
33	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015 , 6, 39088-97	3.3	49
32	A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, 140-6	4	2
31	Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. <i>BMC Cancer</i> , 2014 , 14, 545	4.8	23
30	Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2014 , 53, 277-88	5	28
29	Synaptonemal complex protein 3 is a prognostic marker in cervical cancer. <i>PLoS ONE</i> , 2014 , 9, e98712	3.7	17
28	ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer. <i>Yonsei Medical Journal</i> , 2014 , 55, 1664-71	3	3
27	MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. <i>BMC Cancer</i> , 2014 , 14, 957	4.8	48
26	HER-2 assessment in formalin-fixed paraffin-embedded breast cancer tissue by well-based reverse phase protein array. <i>Clinical Proteomics</i> , 2014 , 11, 36	5	2
25	The role of S100A14 in epithelial ovarian tumors. <i>Oncotarget</i> , 2014 , 5, 3482-96	3.3	24
24	Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. <i>Journal of Translational Medicine</i> , 2013 , 11, 185	8.5	45
23	Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer. <i>Human Pathology</i> , 2013 , 44, 472-9	3.7	22
22	Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. <i>Human Pathology</i> , 2013 , 44, 1365-74	3.7	36

21	Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. <i>Biomarkers</i> , 2013 , 18, 573-9	2.6	21
20	Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer. <i>Cancer Investigation</i> , 2013 , 31, 607-15	2.1	54
19	Clinical significance of serum anti-human papillomavirus 16 and 18 antibodies in cervical neoplasia. <i>Obstetrics and Gynecology</i> , 2013 , 121, 321-329	4.9	4
18	The ON-Q pain management system in elective gynecology oncologic surgery: Management of postoperative surgical site pain compared to intravenous patient-controlled analgesia. <i>Obstetrics and Gynecology Science</i> , 2013 , 56, 93-101	1.9	7
17	Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012 , 160, 100-5	2.4	10
16	Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. <i>Journal of Obstetrics and Gynaecology Research</i> , 2012 , 38, 48-56	1.9	12
15	Nanog signaling in cancer promotes stem-like phenotype and immune evasion. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4077-93	15.9	131
14	The feasibility of robot-assisted laparoscopic myomectomy: Compared with standard laparoscopic and abdominal myomectomy. <i>Korean Journal of Obstetrics & Gynecology</i> , 2011 , 54, 784		0
13	ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. <i>International Journal of Oncology</i> , 2010 , 37, 399-412	4.4	17
12	Accuracy of preoperative tests in clinical stage I endometrial cancer: the importance of lymphadenectomy. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010 , 89, 175-81	3.8	20
11	Autoantibodies against stress-induced phosphoprotein-1 as a novel biomarker candidate for ovarian cancer. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 585-95	5	21
10	Treatment of the patients with abnormal cervical cytology: a "see-and-treat" versus three-step strategy. <i>Journal of Gynecologic Oncology</i> , 2009 , 20, 164-8	4	18
9	Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009 , 47, 1005-12	5.9	9
8	Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2009 , 57, 513-21	3.4	65
7	Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. <i>Cancer Immunology, Immunotherapy</i> , 2009 , 58, 15-23	7.4	377
6	Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. <i>Biomarkers</i> , 2009 , 14, 161-70	2.6	17
5	Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. <i>Cancer Investigation</i> , 2009 , 27, 313-23	2.1	12
4	Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma. <i>Tohoku Journal of Experimental Medicine</i> , 2009 , 218, 129-39	2.4	15

3	Neutrophil-to-lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis. <i>Fertility and Sterility</i> , 2008 , 90, 2073-9	4.8	55
2	Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. <i>Molecular and Cellular Biochemistry</i> , 2008 , 319, 189-201	4.2	9
1	Clinical significance of osteopontin expression in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008 , 134, 909-17	4.9	39